Original article
Neoadjuvant endocrine therapy in breast cancer patients
Raquel Lobo-Cardosoa,, , André Torres Magalhãesb, José Luís Fougob
a Faculty of Medicine, University of Porto, Porto, Portugal
b Breast Center, General Surgery Service, São João Hospital, Porto, Portugal
Recebido 15 Dezembro 2016, Aceitaram 25 Março 2017

The aim of this study is to evaluate if the extension of neoadjuvant endocrine therapy (NET), beyond the conventional time, allows additional downstage of the tumour, in order to perform a breast conservative surgery (BCS), and to analyze if it is a good option for long-term control in patients who refuse or are unfit for surgery.

Patients and methods

We retrospectively reviewed a database containing all patients treated in our institution with NET. All included patients were post-menopausal with primary local disease. The type of response obtained was assessed using modified RECIST criteria.


Thirty-three patients were included. Two patients had tumours with 90% expression of oestrogen receptors and all the others had 100%. The tumour size in the largest diameter was 6.51cm before treatment and 5.18cm after. Eighteen patients achieved a partial response after 10.28 months of therapy. Patients that were proposed to downstage the tumour performed 9.71 months of therapy until surgery and all were submitted to BCS. Progression occurred after 27.5 months.


Endocrine therapy is a feasible option for a longer time to allow additional downstage of the tumour and is a good solution in patients who refuse or are unfit for surgery.

Breast cancer, Neoadjuvant treatment, Endocrine therapy, Estrogen receptor-positive, Breast conserving surgery

Open Access

Licença Creative Commons
Porto Biomedical Journal está licenciado com uma Licença Creative Commons - Atribuição-NãoComercial-SemDerivações 4.0 Internacional.

+ info